Echo Therapeutics (OTCMKTS:ECTE – Get Rating) and Hyperfine (NASDAQ:HYPR – Get Rating) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.
Valuation & Earnings
This table compares Echo Therapeutics and Hyperfine's revenue, earnings per share (EPS) and valuation.
Get Echo Therapeutics alerts:| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Echo Therapeutics | N/A | N/A | N/A | N/A | N/A |
| Hyperfine | $1.50 million | 40.46 | -$64.85 million | ($3.59) | -0.24 |
Echo Therapeutics has higher earnings, but lower revenue than Hyperfine.
Insider & Institutional Ownership
27.7% of Hyperfine shares are held by institutional investors. 7.0% of Echo Therapeutics shares are held by insiders. Comparatively, 26.1% of Hyperfine shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.Profitability
This table compares Echo Therapeutics and Hyperfine's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Echo Therapeutics | N/A | N/A | N/A |
| Hyperfine | -1,479.40% | -54.01% | -49.87% |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Echo Therapeutics and Hyperfine, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Echo Therapeutics | 0 | 0 | 0 | 0 | N/A |
| Hyperfine | 0 | 1 | 2 | 0 | 2.67 |
Hyperfine has a consensus price target of $4.30, suggesting a potential upside of 400.00%. Given Hyperfine's higher possible upside, analysts plainly believe Hyperfine is more favorable than Echo Therapeutics.
Summary
Hyperfine beats Echo Therapeutics on 5 of the 8 factors compared between the two stocks.
About Echo Therapeutics
(Get Rating)
Echo Therapeutics, Inc. is a medical device company, which engages in the development of non-invasive, and wireless continuous glucose monitoring system for use in the diabetes outpatient market. It offers needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose and delivery of topical pharmaceuticals. The company was founded in 1989 and is headquartered in Iselin, NJ.
About Hyperfine
(Get Rating)
Hyperfine, Inc. provides imaging, monitoring, and magnetic resonance imaging products. It offers Swoop Portable MR imaging system to address an unmet need in point-of-care medical imaging through a combination of hardware and software services. The company was incorporated in 2014 and is based in Guilford, Connecticut.
Receive News & Ratings for Echo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Echo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.